New Jersey
Requires Coverage of Comprehensive Biomarker Testing
Yes
Highlighted Disparity
Black individuals in New Jersey are least likely to receive surgical treatment
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in New Jersey is 49.0 and significantly lower than the national rate of 52.8.
- New Jersey ranks 16th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in New Jersey improved by 13%.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer in New Jersey is 32.8%, which is significantly higher than the national rate of 29.7%.
- New Jersey ranks 8th among the 39 states with survival data, placing it in the above average tier.
- Over the last five years, the survival rate in New Jersey improved by 19%.
Early Diagnosis:
- In New Jersey, 28.6% of cases are caught at an early stage, which is not significantly different than the national rate of 28.1%.
- New Jersey ranks 23rd among the 50 states with data on early-stage diagnosis, placing it in the average tier.
- Over the last five years, the early diagnosis rate in New Jersey did not change significantly.
Lung Cancer Treatment
Medicaid Coverage:
- New Jersey was one of the 17 states that required insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- New Jersey ranked 3rd (out of 49 states with available data) with 26.2% of cases undergoing surgery as part of the first course of treatment, which is significantly higher than the national rate of 20.7%.
- This places New Jersey in the above average tier.
- Over the last five years, the percent of cases undergoing surgery in New Jersey did not change significantly.
No Treatment:
- New Jersey ranked 26th (out of 49 states with available data) with 20.5% of cases not receiving any treatment, which is not significantly different than the national rate of 21.0%.
- This places New Jersey in the average tier.
- Over the last five years, the percent of cases receiving no treatment in New Jersey did not change significantly.
Screening
Screening for High Risk:
- In New Jersey, 22.3% of those at high risk were screened, which was not significantly different than the national rate of 18.2%.
- It ranks 9th among all states, placing it in the above average tier.
- Screening rates in this year’s report have been updated to correct an error in the data source and should not be compared to previous reports.
Prevention
Tobacco Use:
- The 2023 smoking rate in New Jersey is 9.1% and significantly lower than the national rate of 11.4%.
- It ranks 6th among all states, placing it in the above average tier.
Radon Exposure:
- In New Jersey, 9.8% of radon test results were at or above the action level recommended by EPA.
- It ranks 8th among all states, placing it in the above average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 46.5 per 100,000 population among Black individuals in New Jersey, significantly lower than the rate of 54.2 among Black individuals nationally, and significantly lower than the rate of 55.5 among white individuals in New Jersey.
- The five-year survival rate is 25.2% among Black individuals in New Jersey, not significantly different than the rate of 27.1% among Black individuals nationally, and significantly lower than the rate of 33.8% among white individuals in New Jersey.
- 22.3% of lung cancer cases are diagnosed at an early stage among Black individuals in New Jersey, significantly lower than the rate of 25.1% among Black individuals nationally, and significantly lower than the rate of 30.0% among white individuals in New Jersey.
- 18.5% of Black individuals with lung cancer in New Jersey underwent surgery, significantly higher than the rate of 17.1% among Black individuals nationally, and significantly lower than the rate of 27.2% among white individuals in New Jersey.
- 25.2% of Black individuals with lung cancer in New Jersey did not receive any treatment, significantly higher than the rate of 22.7% among Black individuals nationally, and significantly higher than the rate of 19.8% among white individuals in New Jersey.
Latino individuals:
- The rate of new lung cancer cases is 28.3 per 100,000 population among Latino individuals in New Jersey, not significantly different than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 55.5 among white individuals in New Jersey.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 25.1% of lung cancer cases are diagnosed at an early stage among Latino individuals in New Jersey, not significantly different than the rate of 23.9% among Latino individuals nationally, and significantly lower than the rate of 30.0% among white individuals in New Jersey.
- 25.3% of Latino individuals with lung cancer in New Jersey underwent surgery, significantly higher than the rate of 21.4% among Latino individuals nationally, and significantly lower than the rate of 27.2% among white individuals in New Jersey.
- 22.5% of Latino individuals with lung cancer in New Jersey did not receive any treatment, significantly lower than the rate of 25.8% among Latino individuals nationally, and significantly higher than the rate of 19.8% among white individuals in New Jersey.
Asian or Pacific Islanders individuals:
- The rate of new lung cancer cases is 25.9 per 100,000 population among Asian or Pacific Islanders individuals in New Jersey, significantly lower than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 55.5 among white individuals in New Jersey.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- 22.2% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in New Jersey, not significantly different than the rate of 23.7% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 30.0% among white individuals in New Jersey.
- 26.1% of Asian or Pacific Islander individuals with lung cancer in New Jersey underwent surgery, not significantly different than the rate of 24.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 27.2% among white individuals in New Jersey.
- 17.5% of Asian or Pacific Islander individuals with lung cancer in New Jersey did not receive any treatment, significantly lower than the rate of 19.8% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 19.8% among white individuals in New Jersey.
Indigenous Peoples:
- Lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in New Jersey due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in New Jersey falling into the average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
New Jersey was one of the states that required insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
New Jersey falls into the average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 29, 2025
